Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
June 24, 2024 06:00 ET
|
Fractyl Health, Inc.
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
June 23, 2024 13:30 ET
|
Fractyl Health, Inc.
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Platform at ADA 2024.
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
June 20, 2024 11:37 ET
|
Zealand Pharma
Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide ...
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
June 14, 2024 09:00 ET
|
Elevai Labs Inc.
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
June 12, 2024 08:30 ET
|
Wave Life Sciences USA, Inc.
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for...
NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk
June 12, 2024 07:00 ET
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk ...
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
June 07, 2024 04:30 ET
|
Boehringer Ingelheim
News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH)...
UMeWorld Announces June 4th webinar Registration Using New AI Investor Chatbot
May 30, 2024 08:00 ET
|
UMeWorld Limited
HONG KONG, May 30, 2024 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTC:UMEWF), a leading company in ESG-based cooking oil and biofuel technologies, today announced the implementation of a cutting-edge AI...
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
May 29, 2024 07:00 ET
|
Fractyl Health, Inc.
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer
May 28, 2024 07:00 ET
|
NodThera
NodThera INC (“NodThera” or the “Company”) NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership...